Health
UK-First AI Case-Finding Pathway Launched to Improve Early Detection of Oesophageal and Gastric Cancer
LONDON, March 19, 2026--A new NHS-first, AI-enabled case-finding pathway has launched across North East Essex, aiming to improve the early detection of Oesophageal and stomach cancers, some of the hardest cancers to diagnose early and among those with the poorest outcomes in England.
About this update from Astrazeneca Plc
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":339,"url":"https://media.zenfs.com/en/business-wire.com/4d2fde0f3e8c0ff16edb05b0db4ab416"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/.y6lblgg1qCZCZf1rMX4OA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTY3OA--/https://media.zenfs.com/en/business-wire.com/4d2fde0f3e8c0ff16edb05b0db4ab416","width":480,"height":339}},"lazy":false},{"type":"text","content":"LONDON, March 19, 2026--(BUSINESS WIRE)--A new NHS-first, AI-enabled case-finding pathway has launched across North East Essex, aiming to improve the early detection of Oesophageal and stomach cancers, some of the hardest cancers to diagnose early and among those with the poorest outcomes in England.","length":301,"tagName":"p"},{"type":"text","content":"Delivered in partnership between AstraZeneca, C the Signs, NHS Suffolk and North East Essex Integrated Care Board, Health Innovation East and GP Primary Choice, the programme represents the first time in England that population-level, AI-driven case finding has been implemented in primary care for Oesophageal and stomach cancers. C the Signs is a UK-developed, AI-powered clinical platform that enables the earliest and most accurate detection of cancer across more than 100 cancer types.","length":490,"tagName":"p"},{"type":"text","content":"Upper gastrointestinal cancers do not currently have a national screening programme and often present with vague, non-specific symptoms. As a result, many patients are diagnosed at a late stage, when treatment options are limited, and outcomes are poor. In England, around four in five oesophageal and stomach cancers are diagnosed at an advanced stage, with survival strongly linked to how early the cancer is detected. This new pathway is designed to address that gap.","length":470,"tagName":"p"},{"type":"text","content":"A proactive approach to finding risk earlier","length":44,"tagName":"p"},{"type":"text","content":""Upper gastrointestinal cancers are some of the hardest cancers to detect early, opportunities for earlier diagnosis are frequently missed," said Dr Bea Bakshi, GP and Co-Founder of C the Signs. "This pathway supports earlier identification of risk and faster access to diagnostics, giving more patients the chance to be diagnose...